Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
104,704,785
-
Share change
-
-9,826,911
-
Total reported value
-
$272,171,990
-
Put/Call ratio
-
198%
-
Price per share
-
$2.60
-
Number of holders
-
138
-
Value change
-
-$30,254,671
-
Number of buys
-
70
-
Number of sells
-
61
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q3 2024
As of 30 Sep 2024,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
104,704,785 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, BAILLIE GIFFORD & CO, Voya Investment Management LLC, Prosight Management, LP, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, ORBIMED ADVISORS LLC, ArrowMark Colorado Holdings LLC, BlackRock, Inc., RENAISSANCE TECHNOLOGIES LLC, and TWO SIGMA INVESTMENTS, LP.
This page lists
139
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.